Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of JNJ-42756493 (Erdafitinib) Tablets
NCT02466815Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of erdafitinib in urothelial carcinoma (UC) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at Day 7, Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours and 2 more. Started Jun 2015; status: completed.
02
Drugs
erdafitinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02466815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02466815.